Continuous glucose monitoring
HYPOGLYCAEMIA
In addition to self-measured PG, which was performed throughout the trial, and PG measurements performed at the clinical site, continuous glucose monitoring (CGM) was conducted from the first dose of the first treatment period until the end of the second treatment period (Dexcom G6; Dexcom, San Diego, CA, USA). CGM data were visible to the participants and the investigators but were not used for titration of basal insulin dose or for reporting hypoglycaemia.